Re: Farmas USA
Re: Farmas USA
JUNO/KITE
Court Decides It Lacks Jurisdiction Before FDA Approval Occurs
absence of evidence that an FDA approval decision of Kite’s lead product candidate axicabtagene ciloleucel “is expected on Defendant’s BLA in the immediate future.”
http://ir.junotherapeutics.com/phoenix.zhtml?c=253828&p=irol-newsArticle&ID=2280888
Re: Farmas USA
Re: Farmas USA
Después de viaje largo , me vuelvo a incorporar.....y veo las ADXS en mínimos .....y en caída libre ....alguna noticia ?....el precio me atrae ,en la franja 6,80/6,90 ...pero el volumen .....me frena....como lo veis ?...
Por otra parte me alegra ver a DVAX en constante crecimiento (bien por zokatira).....y las CEMP están a punto de caramelo ....
Ahora ducha y a esperar al viernes a ver hacia dónde tira el IBB....😉
Re: Farmas USA
Re: Farmas USA
Re: Farmas USA
TGTX
News a media sesión y patadón para arriba
TG Therapeutics, Inc. Announces Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL at the 14th International Conference on Malignant Lymphoma
Combination of TGR-1202 (umbralisib) plus ibrutinib appears well tolerated with no Grade 3/4 transaminitis, pneumonitis, diarrhea, or colitis observed, with longest patients on study 29.5+ months
94% of the CLL patients achieved a CR, PR or PR-L, including 1 patient with a CR, and 3 additional patients with radiographic CR's
79% ORR in patients with MCL, including 1 patient with a CR and 1 additional patient with a radiographic CR
http://ir.tgtherapeutics.com/releasedetail.cfm?ReleaseID=1030224